A New Aura of Relief: Emerging Treatments for Migraines
Pharmacy Times,
Pharmacological options for those who experience migraines come in the form of abortive or preventative therapies.
Pharmacological options for those who experience migraines come in the form of abortive or preventative therapies.
Eli Lilly (LLY -1.7%) announces that Reyvow (lasmiditan) C-V 50 mg and 100 mg tablets, indicated for the acute treatment of…
Close up of woman hands holding a pills.On Friday, the U.S. Food and Drug Administration (FDA) approved a new medication to…
The FDA approves Eli Lilly's (NYSE: LLY ) REYVOW (lasmiditan) for the acute treatment of migraine, with or without aura.
A second Phase 3 clinical trial, SPARTAN, assessing Eli Lilly's (NYSE:LLY) lasmiditan for the acute treatment of migraine, met…
Thinly traded micro cap CoLucid Pharmaceuticals (NASDAQ: CLCD ) is ahead 82% premarket on robust volume in response to its…